Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity

PHASE4RecruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

June 16, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Urinary Bladder, OveractiveEffect of Drug

Interventions

DRUG

Solifenacin with vaginal estrogen cream

Solifenacin 5mg with vaginal conjugated equine estrogen (CEE) 0.625 mg

DRUG

Combination pharmacotherapy

Solifenacin 5mg and Mirabegron 25mg

Trial Locations (1)

RECRUITING

Mackay Memorial Hospital, Taipei

All Listed Sponsors

lead

Mackay Memorial Hospital

OTHER